Felix

Felix Biotechnology is a clinical-stage biopharmaceutical company developing precision bacteriophage therapies to combat antibiotic-resistant bacterial infections. The company utilizes a proprietary engineering platform to design phages that specifically target and kill pathogenic bacteria while minimizing the risk of resistance development. Their lead program, FB-P001, is currently being evaluated for the treatment of chronic Pseudomonas aeruginosa infections in patients with cystic fibrosis. By integrating high-throughput screening with synthetic biology, Felix aims to address the urgent global health challenge of antimicrobial resistance through scalable, targeted microbial interventions.